Physician
Blue Ridge Pain Management Associates, PC
Blue Ridge Pain Management Associates, PC was paid $3.57M by Medicaid between Jan 2018 and Dec 2024, across 50 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 58% of everything it billed.
33Billing provider infoBLUE RIDGE PAIN MANAGEMENT ASSOCIATES, PC
SALEM, VA 24153
SALEM, VA 24153
33aNPI1518118330assigned 10/10/2008
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$3.57M
24GClaims165,363
24DCodes billed50
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in Virginia
Rank by total paid#5 of 25
Median peer was paid$29K
This provider vs. median121×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,178 | $159K | |
| 2019 | 14,945 | $394K | |
| 2020 | 11,117 | $485K | |
| 2021 | 13,617 | $627K | |
| 2022 | 17,468 | $535K | |
| 2023 | 39,457 | $607K | |
| 2024incomplete | 45,581 | $761K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 58% | 48,181 | 42,177 | $2.07M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 16% | 16,517 | 14,601 | $555K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 6.4% | 3,798 | 3,369 | $230K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 5.1% | 1,262 | 1,174 | $181K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 4.9% | 3,907 | 3,465 | $176K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.3% | 1,545 | 1,372 | $117K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.1% | 3,821 | 3,060 | $112K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.5% | 656 | 589 | $54K |
| 62323 | <1% | 217 | 201 | $29K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 2,818 | 2,371 | $13K |
| 99490 | Ccm add 20min | <1% | 925 | 895 | $9K |
| 1036F | <1% | 4,269 | 3,721 | $6K |
38 more codes
| 3288F | <1% | 3,505 | $5K | |
| 1101F | <1% | 2,971 | $4K | |
| 99457 | <1% | 260 | $3K | |
| 99454 | <1% | 182 | $2K | |
| J3490 | Unclassified drugs | <1% | 374 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 25 | $1K |
| 99458 | <1% | 121 | $952.57 | |
| 96103 | <1% | 50 | $530.37 | |
| 77003 | <1% | 164 | $358.66 | |
| 99406 | <1% | 74 | $215.44 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 7,659 | $180.35 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 289 | $103.38 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 237 | $94.43 |
| 96146 | <1% | 47 | $62.22 | |
| 1100F | <1% | 84 | $50.00 | |
| 0518F | <1% | 85 | $50.00 | |
| 99439 | <1% | 17 | $30.59 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 19 | $24.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 7,421 | $0.00 |
| G2196 | Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method | 0% | 148 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 5,516 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 7,352 | $0.00 |
| G8539 | Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment | 0% | 129 | $0.00 |
| G2200 | Patient identified as an unhealthy alcohol user received brief counseling | 0% | 148 | $0.00 |
| G9622 | Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method | 0% | 6,954 | $0.00 |
| G9621 | Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling | 0% | 727 | $0.00 |
| G9991 | Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period | 0% | 45 | $0.00 |
| G8483 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | 0% | 48 | $0.00 |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 4,208 | $0.00 |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 10,856 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 4,743 | $0.00 |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 4,340 | $0.00 |
| G8734 | Elder maltreatment screen documented as negative, follow-up is not required | 0% | 1,005 | $0.00 |
| M1207 | Patient is screened for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety | 0% | 2,864 | $0.00 |
| G2197 | Patient screened for unhealthy alcohol use using a systematic screening method and not identified as an unhealthy alcohol user | 0% | 2,832 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 1,836 | $0.00 |
| 1123F | 0% | 94 | $0.00 | |
| G8418 | Bmi is documented below normal parameters and a follow-up plan is documented | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDRAGOVICH, ANTHONY (PRESIDENT)